New treatment options for allergic rhinitis L. Klimek, C. Harai, S. Chen, O. Pfaar Zentrum für Rhinologie und Allergologie, Wiesbaden
DOI 10.5414/ATX01904
Abstrakt
Allergic rhinitis is a common immunemediated disease that affects a large part of the global population. Its symptoms may not be life-threatening but nonetheless have a strong impact on quality of life and productivity. Current therapeutic options are manifold and include intranasal glucocorticoids, antihistamines and leukotriene receptor antagonists. The current guidelines recommend intranasal glucocorticoids and antihistamines as effective and safe first-line therapies. However, some patients remain uncontrolled with the current treatment options. Therefore, it is necessary to develop new treatment strategies and/or improve current therapy options. Over the last years a few new agents have been developed which may have an impact on the way allergic rhinitis is treated in the nearest future. These include new compounds such as SYK-inhibitors, which inhibit the signalling pathway of the allergic reaction, new antihistamines targeting not only the H1-receptor but also the H3-receptor, new improved glucocorticoids in the form of prodrugs as well as a novel formulation (MP29-02) combining the administration of a nasal antihistamine and glucocorticoid. In allergen-specific immunotherapy, new promising approaches such as intralymphatic and epicutaneous immunotherapy are currently being investigated.
bei einer Überprüfung der Daten haben wir festgestellt, dass uns Ihre E-Mail-Adresse nicht vorliegt. Um Sie gegebenenfalls per eMail kontaktieren zu können, möchten wir Sie bitten, uns diese mitzuteilen. Sie können uns dazu eine E-Mail an [email protected] schicken oder uns unter +49-89-613861-0 telefonisch erreichen.
